The combination was clearly superior in patients with PIK3CA‐mutated HR + mBC as detected in tumor DNA (median PFS: 11 months vs 5.7 months; ORR: 36% vs 16%) or in cfDNA (median PFS: 10.9 months vs 3.7 months; ORR: not reported).47, 48. This evidence concerns the gene PIK3CA and neoplasm.